Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037
October 21 2019 - 7:00AM
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company,
announced today that the U.S. Patent and Trademark Office will
issue on November 5, 2019 U.S. Patent No. 10,10,463,686 entitled
“Immune Modulation With TLR9 Agonists For Cancer Treatment,” which
includes the Company’s investigational therapy tilsotolimod
(IMO-2125).
The patent includes 24 claims directed to methods of treating
melanoma with intratumoral administration of tilsotolimod in
combination with certain immune checkpoint inhibitor therapies
including CTLA-4, PD-1 or PD-L1 proteins. The patent provides
exclusivity through September 2037.
“We are pleased with the continued development of tilsotolimod,
including the breadth and duration of our patent portfolio,” said
Vincent Milano, Idera’s Chief Executive Officer. “This new
patent provides additional intellectual property coverage and
demonstrates our ongoing commitment to tilsotolimod, patients
living with melanoma and innovation.”
About Tilsotolimod (IMO-2125)Tilsotolimod is a
TLR 9 agonist that received Fast Track Designation from the U.S.
Food and Drug Administration (FDA) in 2017 for the treatment of
anti-PD-1 refractory melanoma, in combination with ipilimumab as
well as orphan drug designation from the FDA for the treatment of
melanoma Stages IIb to IV. It signals the immune system to create
and activate cancer-fighting cells (T-cells) to target solid
tumors. Currently approved immuno-oncology treatments,
specifically check-point inhibitors, provide benefit for some
patients, but these therapies are limited in patients whose immune
responses are missing or weak. Intratumoral injections with
tilsotolimod are designed to selectively enable the tumor-specific
T-cells to recognize and attack cancers that remained
elusive and unrecognized by the immune system exposed to checkpoint
inhibitors alone, while limiting toxicity or impact on healthy
cells in the body.
About Idera Pharmaceuticals Harnessing the
approach of the earliest researchers in immunotherapy and the
company’s vast experience in developing proprietary
immunomodulatory platforms, Idera’s TLR agonist development program
is focused on priming the immune system to play a more powerful
role in fighting cancer, ultimately increasing the number of people
who can benefit from immunotherapy. Idera also continues to focus
on the acquisition, development and ultimate commercialization of
drug candidates for both oncology and rare disease indications
characterized by small, well-defined patient populations with
serious unmet needs. To learn more about Idera, visit
www.iderapharma.com.
Idera Forward Looking Statements This press
release contains forward-looking statements within the meaning of
the safe harbor of the Private Securities Litigation Reform Act of
1995 and the Federal securities laws. All statements, other than
statements of historical fact, included or incorporated in this
press release, including statements regarding the Company's
strategy, future operations, collaborations, intellectual property,
cash resources, financial position, future revenues, projected
costs, prospects, clinical trials, plans, and objectives of
management, are forward-looking statements. The words "believes,"
"anticipates," "estimates," "plans," "expects," "intends," "may,"
"could," "should," "potential," "likely," "projects," "continue,"
"will," and "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Idera
cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company's
forward-looking statements. There are a number of important factors
that could cause Idera's actual results to differ materially from
those indicated or implied by its forward-looking statements.
Factors that may cause such a difference include: whether the
Company’s cash resources will be sufficient to fund the Company’s
continuing operations and the further development of the Company’s
programs for the period anticipated; whether interim results from a
clinical trial, such as the preliminary results reported in this
release, will be predictive of the final results of the trial;
whether results obtained in preclinical studies and clinical trials
such as the results described in this release will be indicative of
the results that will be generated in future clinical trials,
including in clinical trials in different disease indications;
whether products based on Idera's technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors as are set forth under
the caption "Risk factors" in the Company’s filings with the
Securities and Exchange Commission. While Idera may elect to do so
at some point in the future, the Company does not assume any
obligation to update any forward-looking statements and it
disclaims any intention or obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Idera Pharmaceuticals
Contact:
Robert A. Doody, Jr.SVP, Investor Relations &
CommunicationsPhone (484) 348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024